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ABSTRACT
Ethionamide (ETH) plays a central role in the treatment of tuberculosis
in  patients resistant to the first-line drugs.  The ETH,  thioamide,  and
thiourea  class  of  antituberculosis  agents  are  pro-drugs  that  are
oxidatively  converted  to  their  active  S-oxides  by  the  flavin
monooxygenase EtaA of  M. tuberculosis,  thus  initiating the chain of
reactions that result in inhibition of mycolic acid biosynthesis and cell
lysis. As shown here, several xanthates are oxidized by purified EtaA to
S-oxide  metabolites  (perxanthates)  implicated  in  their
antimycobacterial  activity.  This  process  is  analogous  to  that
responsible  for  activation  of  ETH.  As  part  of  a  search  for  new lead
candidates,  we  report  here  that  several  xanthates  are  oxidized  by
purified EtaA to S-oxide metabolites (perxanthates) that are implicated
in  the  antimycobacterial  activity  of  these  compounds.  This  process,
which is  analogous to that responsible  for  activation of  ETH, is  also
catalyzed  by  human  flavin  monooxygenase  FMO3.  EtaA  was  not
inhibited in a time-dependent manner during the reaction. Xanthates
with longer alkyl chains were oxidized more efficiently. EtaA oxidized
octyl-xanthate (Km = 5 µM; Vmax = 1.023 nmolP/min; kcat = 5.2 molP/min/
mole) more efficiently than ETH (194 µM; 1.46 nmolP/min; 7.73 nmolP/
min/mole,  respectively).  Furthermore,  the  in  vitro  antimycobacterial
activity  of  four  xanthates against  M. tuberculosis H37Hv was higher
(MIC around 1 µM) than that of ETH (12 µM). 
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Introduction
The  increasing  resistance  of  pathogenic  bacteria  and  viruses
against the available antibiotic and chemotherapeutic agents is one of
the  major  problems  of  modern  healthcare.  At  the  top of  the  list  of
diseases  affected  by  this  resistance  are  AIDS,  influenza,  and
tuberculosis.  The  genetic  variability  of  Mycobacterium underlies  the
current treatment consisting of a cocktail of several “first line” drugs. In
the case of resistance to this treatment, therapy resorts to “second-
line” drugs. The available antituberculosis drugs, as well as those under
development, attack M. tuberculosis at several target points, including
the  bacterial  cell  wall.  Isoniazid  (INH),  ethionamide  (ETH),  and
prothionamide  (PRO)  inhibit  the  enoyl-acyl  carrier  protein  (ACP)
reductase InhA, a key enzyme in cell wall assembly. All three of these
agents  are  prodrugs  that  must  be  activated to  become  effective
(Banerjee  et  al.,  1994;  Johnsson  et  al.,  1995). These  three  drugs
specifically  disrupt  mycolic  acid  synthesis  by  forming  adducts  with
NADH that inhibit InhA, thus blocking  the synthesis of mycolic acids,
key factors in cell envelope permeability, host immunomodulation and
persistence of M. tuberculosis (Mtb) (Daffé et al., 2017). 
Isoniazid is activated by the catalase-peroxidase hemoprotein KatG
(Zhang et al., 1992).  However, ethionamide, a second line drug, is a
sulfur-containing compound that must be activated to its  S-oxide by
the mycobacterial flavin-dependent monooxygenase (EtaA) to exert its
bacteriostatic  action  (Baulard  et  al.,  2000).  Flavoprotein
monooxygenases (FMOs) belong to a large group of flavin oxygenases
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found  in  species  ranging  from  microorganisms  to  mammals.  These
enzymes  are characterized by the NADPH-dependent reduction of an
enzyme-bound  flavin,  leading  to  formation  of  the  active  oxidizing
species, a C4a-flavin (hydro)peroxide (Phillips and Shephard, 2017). 
Human FMO enzymes perform N- or S-oxygenation of nucleophilic
heteroatom-containing  small  exogenous  and  endogenous  molecules
and are  grouped  into  five  classes  depending  on  their  sequence,
structure, organ distribution, genetic control, and substrate specificity.
FMO1 is expressed in human fetal liver and adult human kidney and
intestine;  FMO4  is  expressed  in  kidney  and  brain;  and  the  highly
polymorphic  enzyme FMO2 is  expressed in  the lung.  Today,  26% of
individuals of African descent and 5% of Hispanics carry at least one
allele coding for FMO2.1, which has a very high activity for S-oxidation
of thioureas and thus increases the risk for lung toxicity in tuberculosis
patients treated with ETH  (Krueger et  al.,  2002).  The primary flavin
dependent monooxygenase in human liver is FMO3, which participates
in  the  oxidation  of  a  number  of  nitrogen  and  sulfur-containing
compounds (Cashman and Zhang, 2006).
Classical,  so-called  Baeyer-Villiger  monooxygenases  (BVMOs)
generate reactive (hydro) peroxide intermediates that carry out both
nucleophilic  and  electrophilic  oxygenations.  In  contrast  to  classical
Baeyer-Villiger  reactions,  when  the  BVMO  EtaA  oxidizes  sulfur-
containing  substrates,  its  C4a-adduct  is  most  likely  reacting  as  a
hydroperoxide  rather  than  as  a  peroxide  (Ballou,  2013).  The
heterologous expression and purification of EtaA has made the enzyme
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available  for  testing  the  metabolism  of  heteroatom-containing
compounds under in vitro conditions (Vannelli et al., 2002). Studies of
the reactivity of xanthates with oxygen in the presence of metals have
shown that the primary oxidation products with hydrogen peroxide are
the corresponding sulphines or perxanthates (Silvester et al., 2002).
Xanthates are salts of different derivatives of dithiocarbonic acid
that have a large spectrum of biological effects. These include antiviral,
anticancer, and chelating effects, as well as the inhibition of several
enzymes of importance in intercellular signaling processes  (Adibhatla
et  al.,  2012).  In  1956  Ivanov  et  al.  published  data  that  different
xanthate derivatives have an antibacterial action against Mtb due to
their oxidation to toxic metabolites (Ivanov, 1956).
Here  we  present  the  results  from  the  study  of  metabolism  of
several xanthates by EtaA and FMO3 to S-oxygenated metabolites, and
compare the nature and reactivity  antimycobacterial properties of the
resulting metabolites with those from ETH. The results suggest that this
metabolic activation is essential for their antimycobacterial action.
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Experimental procedures
Materials. Potassium salts of various derivatives of dithiocarbonic
acid (xanthates,   ROCS2K), where R corresponds to alkyl groups with
C1, C2, C3, C3iso, 2-methyl-C3, C4, C5, C8, C10 and C12 carbon atoms,
or  a  cyclohexene  ring;  for  example,  C3  =  propylxanthate  =
CH3CH2CH2COS2-K+,  were  synthesized  as  previously  described  (Rao,
1971).  Ethionamide  (ETH), O-tricyclo[5.2.1.02,6]dec-9-yl-
dithiocarbonate (D609),  NADPH,  bovine  serum  albumin  (BSA),
superoxide dismutase, catalase and all other chemical reagents  were
purchased  from  Sigma–Aldrich Chemical  Co.  (St.  Louis,  MO,  United
States). Human liver  FMO3 was  obtained  from BD Biosciences  (San
Jose,  CA).  Purified  mycobacterial  flavin  monooxygenase  (EtaA)  was
kindly provided by Dr. Clinton Nishida (UCSF, San Francisco, CA).
Spectrophotometric  analyses.  The  metabolism  of  various
xanthates  was  studied  spectrophotometrically.  Stock  solutions  of
various xanthates were prepared in water; C10 and C12 were dissolved
in DMSO; ETH was dissolved in acetonitrile.  The final organic solvent
concentration was held to 0.1% (v/v).
1. Xanthates, ETH, and hydrogen peroxide: 
Spectral changes of xanthates and ETH in 0.1 M phosphate buffer,
pH  = 7.4,  were  determined  after  incubation  with  10  mM hydrogen
peroxide.
2. Xanthate, ETH, and EtaA:
The final reaction medium contained EtaA (400 nM), bovine serum
albumin (BSA, 0.1 mg/mL), superoxide dismutase (100 U/mL), catalase
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(100  U/mL),  KCl  (100  mM),  NADPH  (200  µM)  and  different
concentrations of xanthates in HEPES buffer (50 mM, pH = 7.5). When
used,  the  NADPH  regenerating  system  consisted  of  glucose-6-
phosphate (2.5 mM) and glucose-6-phosphate dehydrogenase (2 U/mL).
After 2 min pre-incubation at 37 oC the reaction was initiated by adding
the enzyme to the sample cuvette and an equal volume of water to the
reference  cuvette  in  a Varian  Cary  300 Bio dual-beam
spectrophotometer (Varian, Inc., Palo Alto, CA).
Spectral scans between 250 and 400 nm were recorded every 30 s
at a scan rate of 1515 nm/min and a spectral bandwidth of 4 nm. A
baseline of the reaction mixture in the two cuvettes was collected prior
to  addition  of  the  enzyme.  The rates  of  substrate consumption  and
product formation were determined at 301 (ε = 17,600 M-1cm-1) and
347 (ε = 10,400 M-1cm-1) nm, respectively (Hao et al., 2000).
Single-wavelength kinetic studies were conducted at either 321 or
347  nm  for  the  observation  of  either  NADPH  (ε =  4,752  M-1cm-1)
consumption or product formation, respectively.
3. Xanthates and FMO3:
The same experimental protocol as above was used to follow the
spectral  changes  between  250  and  400  nm  after  incubation  of
xanthates  with  FMO3.  For  kinetic  studies,  both  the  reference  and
sample  cuvettes  were  charged  with  a  500  l  volume  of  buffer
containing the desired xanthate at a 200  M final concentration. The
reaction was started by adding NADPH (200  µM) and enzyme protein
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(50 μg, 60 pmoles FAD) to the sample cuvette and its progress followed
by recording the absorption changes at 347 nm for 5 min at 37 oC.
Antimycobacterial activity of xanthates and ETH. The in vitro
antimycobacterial activity of C2, C5, C8, D609 and ETH was determined
through  the proportional  method  of  Canetti (Canetti  et  al.,  1969)
towards reference strain  M. tuberculosis H37Rv. Each compound was
tested at seven concentrations – 10 μg/ml, 5 μg/ml, 2 μg/ml, 1 μg/ml,
0.5 μg/ml, 0.2 μg/ml and 0.1 μg/ml in DMSO. Tubes with Löwenstein-
Jensen medium (5 ml) containing tested compounds and those without
them  (controls)  were  inoculated  with  0.1  ml  suspension  of  M.
tuberculosis H37Rv (105 cells/ml) and incubated for 45 days at 37 °C.
The ratio between the number of colonies of  M. tuberculosis grown in
medium containing compounds and the number of colonies in control
medium were  calculated and expressed as  percentage of  inhibition.
The MIC is defined as the minimum concentration of compound (in M)
required to inhibit bacterial growth completely (0% growth).
Statistics.  Non-linear and linear regression analyses to calculate
the enzyme kinetic parameters were done using GraphPad Prism 6.0
software. Paired  t-test  was  applied  for  statistical  comparison  of  the
enzyme activity data. 
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Results
1. Oxidation of xanthates and ETH by hydrogen peroxide.
Hydrogen  peroxide  oxidizes  xanthates  and  ETH  to  single
metabolites: perxanthate or sulfine (λmax at 347 nm) and ethionamide-
S-oxide (λmax around 350 nm), respectively (Fig. 1 aA,bB). 
The sharper increase of perxanthate over time compared to that of
ETH-S-oxide was not only due to the higher extinction coefficient of the
former - ε =10,400 M-1cm-1 (Hao et al., 2000) versus ε = 6,000 M-1cm-1
(Vannelli et al., 2002). The rate of oxidation of C5-xanthate by H2O2 to
its  metabolite  was  more  than  two  times  faster  (2.34  nmoles/min)
compared to that of ETH (1.0 nmoles/min). It is important to note that
the oxidation of ETH to ETH-SO by H2O2 occurs without the assistance
of any cofactor such as NAD+ (Laborde et al., 2016).
2. Metabolism of xanthates by EtaA.
Scanning  Kinetics.  Initial  metabolism  studies  with  an  NADPH
regenerating  system  and  EtaA  enabled  the  direct  observation  and
comparison  of  product  formation  and  substrate  consumption  rates.
These  data  for  a  sampling  of  xanthate  substrates are  presented in
Table 1 and Fig. 2a2A.
The substrate consumption (decrease of absorption at 301 nm) and
product  formation  (increase  of  absorption  at  347  nm)  rates  after
incubation  with  EtaA  correlate  well,  indicating  conversion  of  the
substrate  to  a  single  product,  the  corresponding  perxanthate.  The
presence of a clear isosbestic point at 321 nm (Fig. 2Ab) supports the
conclusion that the substrate is converted to a single product. It is to be
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noted that with the longer straight chain alkyl-xanthates (i.e. decyl and
dodecyl-xanthates) there was a discrepancy between the higher rates
of substrate depletion and the lower rates of product formation. This
discrepancy could be due to aggregation and subsequent precipitation
of  the  product  of  the  longer  substrates  in  the  aqueous  solution.
Xanthates bearing cyclic or branched side-chains (2-methyl-C3, Cyclo
and D609) were metabolized by EtaA at significantly slower rate. 
Steady-State Kinetics. The dependence of the C8 oxidation rate
on the substrate concentration follows the Michaelis-Menten equation.
Fig.  3  presents  the  best  fit  through  the  data-set  obtained  and  the
approximate kinetic values are based on that fit. The maximum rate of
oxidation  of  C8-xanthate  by  EtaA  was  practically  the  same  as  that
previously obtained for ETH (Vmax=1.46 nmolP/min and 7.73 molP/min/
molEe, respectively). It is important to note that the kcat values for the
oxidation of most substrates by EtaA are nearly the same. This is due
to the fact that the rate limiting step in the FMO catalytic cycle is the
release of water from the enzyme with the concomitant dehydration of
the C4a-flavin hydroxide (Beaty and Ballou, 1981).
However, the Km value shows that C8 has a much higher affinity for
EtaA than ETH (Km=5 μM versus 194 μM, respectively) (Vannelli et al.,
2002). Stopped  flow  studies  show  that  the  Km values  for  S-
oxygenatable  substrates  depend  largely  on  their  reactivity  with  the
hydroxyperoxyflavin  rather  than  on  their  interaction  with  enzyme
protein. The determining factor is the nucleophilicity of the sulfur atom
(Poulsen  and  Ziegler,  1995),  which  in  all  tested  xanthates  is
11
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significantly  higher  than  that  of  ETH. The  higher  reactivity  of  the
xanthates  was  consistent  also  with  the  higher  rate  of  oxidation  by
hydrogen peroxide.
3. Metabolism of xanthates by human isozyme FMO3.
Similar results were also obtained by examining the metabolism of
xanthates to S-oxidative products (perxanthates) by human liver FMO3
(Fig. 4).
The results from tracking the rate of formation of the perxanthate
metabolites from different xanthates by FMO3 are listed in Table 2. 
The  results  show  that  the  rate  of  S-oxidation  increases  with
increasing number of  carbon atoms in the alkyl  chain substituent in
incubations of xanthates with EtaA and FMO3. Thus, C8 was oxidized
most rapidly to its perxanthate by FMO3. Again, the derivatives with
cyclic or branched side-chains substituents (D609, C3iso and 2-methyl-
C3) were oxidized at a slower rate. Surprisingly the two xanthates with
longest alkyl chain substituents (C10 and C12), which are insoluble in
water (stock solution dissolved in DMSO), were oxidized by FMO3 much
faster than the corresponding water soluble xanthates. This difference
in  the  kinetic  properties  of  the  two  flavin  monooxygenases  with
substrates of different lipophilicities may be due to the fact that insect
cell  supersomes  containing  FMO3 were  employed  for  these  studies.
Although the concentration of DMSO in the samples was kept low (less
than 1%), an increase of the catalytic activity is possible in supersomes
due to the presence of a detergent, as previously reported  (Reddy et
al., 2010).
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4. Antimycobacterial activity of different xanthates and ETH.
The results on the antimycobacterial activity of selected xanthates
relative to that of ETH are presented in Table 3.
The xanthates with short to medium alkyl chain substituents had
MIC values ten times lower than that of ETH, whereas the MIC value of
D609, compound with a cyclic substituent, was comparable to that of
ETH.
As a whole, some of the xanthate analogues tested in this study
showed a moderate level of bacteriostatc antimycobacterial activity, in
most cases comparable or even higher than that of the reference drug
ethambutol (Jadaun et al., 2007). 
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Discussion
The  present  results  show  that  the  xanthates  are  primarily  or
exclusively  oxidized  by  EtaA  to  the  corresponding  sulfines  or
perxanthates, which have a maximum absorption peak at 347 nm. The
calculated kinetic parameters for production of these metabolites were
much betterfaster than those for oxidation of ETH by the same enzyme.
The xanthate metabolites produced by EtaA appeared to be identical to
those obtained upon incubation with hydrogen peroxide. The spectral
properties of the xanthates suggest that they may be useful substrates
to determine FMO activity in biological samples if the SOD and catalase
activity in these samples is inhibited.  The ready synthetic access to
xanthate  derivatives  may provide  access  to  compounds  with  higher
anti-mycobacterial activities.
There  is  a  large  group  of  thiourea  prodrugs  with  potent
bacteriostatic anti-mycobacterial activity that must be oxidized by EtaA
to  exert  their  action.  Thus,  thioacetazone  (THZ)  is  oxidized  into  its
active form, 2-ethyl-4-amidopyridine. It has a relatively low affinity (Km
= 131 ± 29  μM) for EtaA (Qian and Ortiz de Montellano, 2006; Alahari et al.,
2007). Isoxyl (thiocarlide; 4,4′-diisoamyloxydiphenylthiourea) is likewise
activated by EthAEtaA, although its anti-mycobacterial activity differs in
that it inhibits the synthesis of oleic acid as well as that of mycolic acid
(Phetsuksiri  et  al.,  2003).  Other  compounds  with  thioamide  and
thiourea  groups,  including  thiobenzamide,  isothionicotinamide, and
prothionamide are oxidized by EtaA and human FMO enzymes (Vannelli
et al., 2002; Nishida and Ortiz de Montellano, 2011).
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The spectroscopic results in the oxidation of xanthates by EtaA and
the published data on the possible sulfur-oxidized metabolites implicate
the following scheme in the metabolism of xanthates by EtaA (Fig. 5).
Thus  the  killing  efficacy of  different  thioamide  and  thiourea
compounds against Mtb supports the idea that it  ismay be possible to
improve  their  clinical application  through  dosage  reduction,  thus
minimizing  side  effects  and improving  patient  compliance.  This
approach can in principle be achieved by manipulating EtaA efficiency:
a. I By  increasing  EtaA  activity  by  boosting  the  enzyme  gene
expression.
b. By compounds with higher affinity for EtaA. Thus, as decreasing
the dose achieves the same efficacy at reduced toxicity.
In the context of a comparison of anti-bacterial effects of ETH and
alkyl  chain  xanthates derivatives  it  should  be  considered that  the
actual  active  ETH metabolite  is  not  ETH-SO, but  the  so called  ETH*
(Hanoulle  et  al.,  2006),  a  metabolite  with  still  unknown  molecular
characteristics which  accumulates within the bacterial cells whilst the
other ETH derivatives were exclusively found in the extracellular milieu.
Whether the physicochemical characteristics of the peraxanthate have
allowed more efficient penetration into the bacterial cell and therefore
greater  antibacterial  activity,  this  remains  to  be
demonstratedestablished. 
In  conclusion,  the  xanthates  examined  exhibit  high  affinity  for
FMOs that oxidized them to the corresponding S-oxides (perxanthates),
apparently without altering the activating enzyme activity. They could
be used as test substrates for rapid and selective determination of FMO
activity in various biological media. Xanthates have antimycobacterial
15
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activity against M. tuberculosis H37Rv comparable to that of ETH. The
synthesis  of  further  xanthate  derivatives  would  appear  to  be  a
promising route to compounds with higher antimycobacterial activity.
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Figures Legends
Fig. 1. Spectral changes of aA. C5-xanthate (50 μM) and bB. ETH (200
μM)  in  0.1  M  phosphate  buffer,  pH  7.4,  by  10  mM  hydrogen
peroxide.
Fig.  2.  aA. Spectroscopic  characteristics  of  metabolism  of  octyl
xanthate (80  µM) by  EtaA  measured  over  20  min;  bB. Changes  in
absorption over time at 301 (blue), 321 (black), and 347 (red) nm.
Fig. 3. Steady-state kinetics of the oxidation of octyl xanthate by EtaA.
The red line represents the best nonlinear curve-fit (r2= 0.9749). The
Michaelis-Menten  parameters  are  represented  as  means  ±  SD from
three different experiments.
Fig. 4. A. Spectroscopic characteristics of cyclohexyl xanthate (80 µM)
after  incubation  with  human  FMO3;  B.  Rate  of  metabolism  of  2-
methylpropyl xanthate (80 µM) on incubation with human FMO3.
Fig. 5. Structure of ethionamide and Proposed proposed scheme of
S-oxidation of xanthates by EtaA to perxanthates. A similar reaction is
mediated by human FMO3.
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Table 1. Metabolism of different xanthates (100 µМ) by EtaA (400
nM); rates of decrease of substrate at 301 nm and increase of product
at  347  nm are  presented.  Values  are  the  means  ±  SD from three
different experiments.
Xanthate
V301 nm
(nmoles/min)
V347 nm
(nmoles/m
C3 - 1.27 ± 0.07
0.97 ±
0.077
2-methyl-
C3
-  0.38 ±
0.06
0.22 ±
0.012
C4 - 1.57 ± 0.12
0.93 ±
0.065
C5 - 1.53 ± 0.09
0.74 ±
0.052
C8 - 1.35 ± 0.08
0.90 ±
0.072
Cyclo - 0.8 ± 0.07
0.71 ±
0.064
C10 - 2.47 ± 0.18
0.49 ±
0.110
C12 - 1.51 ± 0.10
0.03 ±
0.007
D609 - 0.89 ± 0.08
0.58 ±
0.040
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Table 2. Rate of formation of perxanthate metabolites at 347 nm
from different xanthates (200  M final concentration) after incubation
with FMO3 (50 μg, 60 pmoles FAD) in the presence of NADPH (200 M).
Values are means of three different experiments.
Xanthat
es
V
(nmolP/min)
Linear regression
(r2)
C1 0.34 0.847
C2 0.44 0.958
C3 0.78 0.911
C3iso 0.46 0.891
2-Methyl-C3 0.38 0.803
C4 0.78 0.998
C5 0.84 0.895
C8 0.95 0.860
C10 2.54 0.988
C12 3.43 0.985
Cyclo 0.56 0.835
D609 0.38 0.812
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Table 3. Antimycobacterial activity of selected xanthates and ETH
as measured by the proportional method.
Compound MIC (µM)
C2 - xanthate 1.25
C5 - xanthate 0.99
C8 - xanthate 2.05
D609 18.8
Ethionamide 12.0
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